In the BioHarmony Drug Report Database

"Preview" Icon

Umbralisib

Ukoniq (umbralisib) is a small molecule pharmaceutical. Umbralisib was first approved as Ukoniq on 2021-02-05. It is used to treat b-cell lymphoma marginal zone and follicular lymphoma in the USA. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. In addition, it is known to target casein kinase I isoform epsilon. Ukoniq’s patents are valid until 2035-05-26 (FDA).

 

Trade Name

 

Ukoniq
 

Common Name

 

umbralisib
 

ChEMBL ID

 

CHEMBL3948730
 

Indication

 

b-cell lymphoma marginal zone, follicular lymphoma
 

Drug Class

 

Phosphatidylinositol 3-kinase inhibitors

Image (chem structure or protein)

Umbralisib structure rendering